A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Summary

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Inavolisib

  Inavolisib will be administered orally as per schedule specified in the respective arms.

• Drug
  Bevacizumab

  Bevacizumab IV will be administered as per schedule specified in the respective arm.

• Drug
  Cetuximab

  Cetuximab IV will be administered as per schedule specified in the respective arm.

• Drug
  Atezolizumab

  Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.

• Drug
  Tiragolumab

  Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.

• Drug
  SY-5609

  SY-5609 will be administered by mouth as per schedule specified in the respective arm.

Locations (76)